Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder

✍ Scribed by Lenard A. Adler; Michael Liebowitz; William Kronenberger; Meihua Qiao; Richard Rubin; Millie Hollandbeck; Ahmed Deldar; Kory Schuh; Todd Durell

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 183 KB
• Volume: 26
• Category: Article
• ISSN: 1091-4269
• DOI: 10.1002/da.20549

✦ Synopsis

Background:

To evaluate the effect of atomoxetine (atx) on attention-deficit/hyperactivity disorder (adhd) and comorbid social anxiety disorder in adults.

Methods:

Randomized, double-blind, placebo-controlled, conducted in adults with adhd and social anxiety disorder. patients received 40-100 mg atx (n=224) or placebo (n=218) for 14 weeks following a 2-week placebo lead-in period. efficacy measures included the conners' adult adhd rating scale: investigator-rated: screening version (caars:inv:sv), liebowitz social anxiety scale (lsas), clinical global impression-overall-severity (cgi-o-s), state-trait anxiety inventory (stai), social adjustment scale-self report (sas), and adult adhd quality of life scale-29 (aaqol). safety and tolerability were also assessed.

Results:

Atx mean change (-8.7+/-10.0) from baseline (29.6+/-10.4) on caars:inv:sv total adhd symptoms score was significantly greater than placebo mean change (-5.6+/-10.2) from baseline (31.2+/-9.4; p<.001). atx mean change (-22.9+/-25.3) from baseline (85.3+/-23.6) on lsas total score was significant compared to placebo mean change (-14.4+/-20.3) from baseline (82.1+/-21.3; p<.001). the visit-wise analysis revealed greater improvement on the caars:inv:sv total adhd symptoms score and lsas total score for atx at every time point throughout the study (p values

Conclusions:

Atx monotherapy effectively improved symptoms of adhd and comorbid social anxiety disorder in adults and was well tolerated.